July 17, 2008 - Toyota Tsusho America, Inc. (New York, NY) and Nippon Kayaku Co., Ltd. (Tokyo, Japan) announced the formation of a new joint venture company, GlycoMark, Inc., dedicated to the discovery and commercialization of novel biomarkers for diabetes. The company is located in New York, NY and the Piedmont Triad Research Park in Winston-Salem, NC.
Toyota Tsusho America, Inc., Nippon Kayaku Co., Ltd., and the BioMarker Group (Kannapolis, NC) have worked together as partners to commercialize the GlycoMark(R) diabetes blood test over the past few years prior to establishing the new company.
With increasing clinical acceptance and commercial success of the GlycoMark(R) blood test, a solid foundation has now been built to position GlycoMark, Inc. as a leader in the field of diabetes diagnostics... [PDF] GlycoMark's Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
August
(12)
- Lilly and Boehringer Ingelheim : New data show Dul...
- Home Diagnostics: FDA Clearance for TRUE2go, TRUEr...
- Activx Biosciences : Positive Phase Ib and IIa Cli...
- Amylin and Lilly : Context for FDA Alert for BYETTA
- Intercept Pharmaceuticals Raises $25 Million, Fund...
- SemBioSys submits IND for safflower-produced insul...
- Silence Therapeutics to receive $1.9m Milestone Pa...
- Formation of GlycoMark, Inc., a Joint Venture to D...
- Eisai China : License Agreement in China for alpha...
- Sanofi-aventis : Newly Published Study Results Sho...
- Allon Therapeutics : U.S. patent for lead product ...
- UCB : not-approvable letter from FDA for lacosamid...
-
▼
August
(12)
Monday, August 11, 2008
Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
Libellés :
GlycoMark,
Nippon Kayaku,
Toyota Tsusho America